Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease

BackgroundHuntington's Disease (HD) is an inherited autosomal dominant genetic disorder in which neuronal tissue degenerates. The pathogenesis of the disease appears to center on the development of protein aggregates that arise initially from the misfolding of the mutant HD protein. Mutant huntingtin (Htt) is produced by HD genes that contain an increased number of glutamine codons within the first exon and this expansion leads to the production of a protein that misfolds. Recent studies suggest that mutant Htt can nucleate protein aggregation and interfere with a multitude of normal cellular functions.ResultsAs such, efforts to find a therapy for HD have focused on agents that disrupt or block the mutant Htt aggregation pathway. Here, we report that short guanosine monotonic oligonucleotides capable of adopting a G-quartet structure, are effective inhibitors of aggregation. By utilizing a biochemical/immunoblotting assay as an initial screen, we identified a 20-mer, all G-oligonucleotide (HDG) as an active molecule. Subsequent testing in a cell-based assay revealed that HDG was an effective inhibitor of aggregation of a fusion protein, comprised of a mutant Htt fragment and green fluorescent protein (eGFP). Taken together, our results suggest that a monotonic G-oligonucleotide, capable of adopting a G-quartet conformation is an effective inhibitor of aggregation. This oligonucleotide can also enable cell survival in PC12 cells overexpressing a mutant Htt fragment fusion gene.ConclusionSingle-stranded DNA oligonucleotides capable of forming stable G-quartets can inhibit aggregation of the mutant Htt fragment protein. This activity maybe an important part of the pathogenecity of Huntington's Disease. Our results reveal a new class of agents that could be developed as a therapeutic approach for Huntington's Disease.

[1]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Harry T Orr,et al.  Ataxin-1 Nuclear Localization and Aggregation Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 1998, Cell.

[5]  C. Ross,et al.  Polyglutamine fibrillogenesis: The pathway unfolds , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Gusella,et al.  Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine , 2007, Journal of Molecular Neuroscience.

[7]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[8]  C. C. Hardin,et al.  Monovalent cation induced structural transitions in telomeric DNAs: G-DNA folding intermediates. , 1991, Biochemistry.

[9]  M. Bansal,et al.  Hairpin and parallel quartet structures for telomeric sequences. , 1992, Nucleic acids research.

[10]  H. Zoghbi,et al.  Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. , 2005, Human molecular genetics.

[11]  J. Feigon,et al.  Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Weigel,et al.  Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. , 1999, Human molecular genetics.

[13]  O. Fedoroff,et al.  NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. , 1998, Biochemistry.

[14]  N. Jing,et al.  Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. , 2003, DNA and cell biology.

[15]  Ronald Wetzel,et al.  Amyloid-like features of polyglutamine aggregates and their assembly kinetics. , 2002, Biochemistry.

[16]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.

[17]  V A Zakian,et al.  Telomeres: Beginning to Understand the End , 1995, Science.

[18]  Dipankar Sen,et al.  A sodium-potassium switch in the formation of four-stranded G4-DNA , 1990, Nature.

[19]  H. Lehrach,et al.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. De Clercq,et al.  Stability-Activity Relationships of a Family of G-tetrad Forming Oligonucleotides as Potent HIV Inhibitors , 2000, The Journal of Biological Chemistry.

[21]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[22]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[23]  P. Bates,et al.  Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. , 2003, Nucleic acids research.

[24]  R. Wetzel,et al.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human molecular genetics.

[25]  P. Balagurumoorthy,et al.  Structure and stability of human telomeric sequence. , 1994, The Journal of biological chemistry.

[26]  S. Neidle,et al.  Inhibition of human telomerase by a G-quadruplex-interactive compound. , 1997, Journal of medicinal chemistry.

[27]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[28]  Y. Pommier,et al.  Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. , 1996, Biochemistry.

[29]  D. Tagle,et al.  Mutant Huntingtin Expression in Clonal Striatal Cells: Dissociation of Inclusion Formation and Neuronal Survival by Caspase Inhibition , 1999, The Journal of Neuroscience.

[30]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[31]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[32]  M. MacDonald,et al.  Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation , 2005, BMC Neuroscience.

[33]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.